Carlos Andrés Roldán Hernández

Mr. Carlos Andrés Roldán Hernández

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EGEster Gonzalez-Sanchez
Ester Gonzalez-Sanchez
CHCarlos Andrés Roldán Hernández
Carlos Andrés Roldán Hernández
ARAna Martín Ramírez
Ana Martín Ramírez
LCLucia Garcia Collado
Lucia Garcia Collado
Laura FouassierLaura Fouassier
Laura Fouassier
JVJavier Vaquero
Javier Vaquero
Zinc finger E-box binding homeobox 1 (ZEB1) is a member of the zinc finger homeodomain transcription factor family, with a pivotal role in regulating the epithelial to mesenchymal transition (EMT) process. Increasing evidence suggests that ZEB1 is overexpressed in liver tumors, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), and it correlates with advanced disease features and reduced overall survival. Here, we examine ZEB1 molecular functions, regulatory networks and contribution to tumorigenesis. We also discuss the emerging therapeutic strategies and future research directions aimed at targeting the ZEB1 molecular network to improve the outcome of liver cancer patients.

6 July 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
EGEster Gonzalez-Sanchez
Ester Gonzalez-Sanchez
MVMarie Vallette
Marie Vallette
LCLucia Garcia Collado
Lucia Garcia Collado
ARAashreya Ravichandra
Aashreya Ravichandra
MMMirko Minini
Mirko Minini
JVJavier Vaquero
Javier Vaquero
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive tumour from the biliary tree that is characterized by a prominent desmoplastic stroma, mainly composed of cancer-associated fibroblasts (CAF), and a poor prognosis due to its late clinical presentation and the lack of effective non-surgical treatments. Current therapies still include chemotherapeutic combinations of gemcitabine and cisplatin for the majority of the patients showing poor results due the apparition of resistance. This situation led us to interrogate the potential role in the development of chemoresistance of ZEB1, an EMT-inducing transcription factor (EMT-TF) that we previously identified as a pro-tumorigenic factor in tumour cells and CAF of iCCA. By analysing human CCA samples and sc-RNAseq public databases, we show here that ZEB1 is present in the tumour microenvironment of all iCCA patients tested and is prominently expressed by the myofibroblastic CAF subpopulation (myCAF). Using cellular models of CAF, we show that cells depleted for ZEB1 are more sensitive to gemcitabine and cisplatin, via a mechanism involving the direct regulation of the anti-apoptotic gene BCL2. Moreover, ZEB1 expressing CAF protect iCCA tumour cells against the toxicity of the chemotherapeutic drugs through the release of paracrine soluble factors, including CTGF, IL6 and IL8, an event that could be reversed by the BCL2 inhibitor venetoclax. Therefore, our results point to the use of BCL2 inhibitors as a way to improve the efficacy of current chemotherapeutic regimens in iCCA patients.

Verified
Journal Article
Open access
PDF file
EGEster Gonzalez-Sanchez
Ester Gonzalez-Sanchez
CHCarlos Andrés Roldán Hernández
Carlos Andrés Roldán Hernández
ARAna Martín Ramírez
Ana Martín Ramírez
LCLucia Garcia Collado
Lucia Garcia Collado
Laura FouassierLaura Fouassier
Laura Fouassier
JVJavier Vaquero
Javier Vaquero
The following reference [84] has been retracted and has to be removed from the original publication